Indivior Announces Patrick Barry as Chief Commercial Officer
Indivior PLC (Nasdaq/LSE: INDV) has appointed Patrick Barry as Chief Commercial Officer, effective June 2, 2025. Barry, a seasoned pharmaceutical executive with over 30 years of experience, will lead the company's commercial growth strategy and operations, focusing on advancing the treatment of opioid use disorder through SUBLOCADE®. Previously serving as executive vice president and chief commercial officer at Endo Pharmaceuticals, Barry managed commercial activities across three U.S. business segments with approximately $2 billion in revenue. His extensive career includes over two decades at Sanofi in various senior leadership positions. Barry holds an MBA from Cornell University and will join Indivior's executive committee.
Indivior PLC (Nasdaq/LSE: INDV) ha nominato Patrick Barry Chief Commercial Officer, con decorrenza dal 2 giugno 2025. Barry, un esperto dirigente farmaceutico con oltre 30 anni di esperienza, guiderà la strategia di crescita commerciale e le operazioni dell'azienda, concentrandosi sul progresso del trattamento del disturbo da uso di oppioidi con SUBLOCADE®. In precedenza, come vicepresidente esecutivo e Chief Commercial Officer presso Endo Pharmaceuticals, Barry ha gestito le attività commerciali in tre segmenti di business negli Stati Uniti, con un fatturato di circa 2 miliardi di dollari. La sua lunga carriera comprende oltre vent'anni in Sanofi, ricoprendo diversi ruoli di leadership senior. Barry è in possesso di un MBA conseguito alla Cornell University e entrerà a far parte del comitato esecutivo di Indivior.
Indivior PLC (Nasdaq/LSE: INDV) ha designado a Patrick Barry como Director Comercial, con efecto a partir del 2 de junio de 2025. Barry, un ejecutivo farmacéutico con más de 30 años de experiencia, liderará la estrategia de crecimiento comercial y las operaciones de la compañía, enfocándose en avanzar en el tratamiento del trastorno por uso de opioides mediante SUBLOCADE®. Anteriormente, como vicepresidente ejecutivo y director comercial en Endo Pharmaceuticals, Barry gestionó las actividades comerciales en tres segmentos de negocio en EE. UU., con ingresos aproximados de 2 mil millones de dólares. Su extensa carrera incluye más de dos décadas en Sanofi, desempeñando diversos cargos de liderazgo senior. Barry posee un MBA de la Universidad de Cornell y se unirá al comité ejecutivo de Indivior.
Indivior PLC (나스닥/LSE: INDV)는 패트릭 배리를 2025년 6월 2일부로 최고상업책임자(CCO)로 임명했습니다. 30년 이상의 경력을 가진 제약업계 베테랑인 배리는 SUBLOCADE®를 통한 오피오이드 사용장애 치료의 발전에 중점을 두고 회사의 상업 성장 전략과 운영을 이끌 예정입니다. 이전에는 Endo Pharmaceuticals에서 부사장 겸 최고상업책임자로서 미국 내 세 개 사업 부문의 상업 활동을 관리하며 약 20억 달러의 매출을 담당했습니다. 또한, 배리는 Sanofi에서 20년 이상 다양한 고위 리더십 직책을 역임한 경력이 있습니다. 그는 코넬 대학교에서 MBA를 취득했으며 Indivior의 경영위원회에 합류할 예정입니다.
Indivior PLC (Nasdaq/LSE : INDV) a nommé Patrick Barry au poste de Chief Commercial Officer, à compter du 2 juin 2025. Barry, cadre pharmaceutique expérimenté avec plus de 30 ans d'expérience, dirigera la stratégie de croissance commerciale et les opérations de l'entreprise, en se concentrant sur l'amélioration du traitement du trouble lié à l'usage d'opioïdes grâce à SUBLOCADE®. Auparavant, en tant que vice-président exécutif et Chief Commercial Officer chez Endo Pharmaceuticals, Barry a géré les activités commerciales sur trois segments d'affaires américains, générant environ 2 milliards de dollars de revenus. Sa carrière étendue comprend plus de vingt ans chez Sanofi à divers postes de direction senior. Barry est titulaire d'un MBA de l'université Cornell et rejoindra le comité exécutif d'Indivior.
Indivior PLC (Nasdaq/LSE: INDV) hat Patrick Barry zum Chief Commercial Officer ernannt, wirksam ab dem 2. Juni 2025. Barry, ein erfahrener Pharma-Manager mit über 30 Jahren Berufserfahrung, wird die kommerzielle Wachstumsstrategie und die operativen Abläufe des Unternehmens leiten, mit Schwerpunkt auf der Weiterentwicklung der Behandlung der Opioidgebrauchsstörung durch SUBLOCADE®. Zuvor war er als Executive Vice President und Chief Commercial Officer bei Endo Pharmaceuticals tätig, wo er die kommerziellen Aktivitäten in drei US-Geschäftsbereichen mit einem Umsatz von etwa 2 Milliarden US-Dollar verantwortete. Seine umfangreiche Karriere umfasst über zwei Jahrzehnte bei Sanofi in verschiedenen leitenden Positionen. Barry besitzt einen MBA der Cornell University und wird dem Führungsausschuss von Indivior beitreten.
- Appointment of highly experienced executive with 30+ years in pharmaceutical industry
- Strong track record in managing $2 billion revenue portfolio at Endo Pharmaceuticals
- Extensive experience in product launches and market development from Sanofi tenure
- None.
Seasoned commercial executive with more than 30 years of pharmaceutical experience
"Patrick is an accomplished and respected commercial leader whose strong track record driving growth in branded medicines make him an excellent addition to the executive team," said Joe Ciaffoni, Chief Executive Officer. "Patrick's breadth and depth of commercial experience will be instrumental in delivering on the Company's potential."
Barry has more than 30 years of commercial leadership experience in the pharmaceutical industry. He brings a track record of building and transforming high-performing commercial organizations to deliver sustained revenue growth across multiple product portfolios.
Prior to joining Indivior, Barry served since 2020 as executive vice president and chief commercial officer for Endo Pharmaceuticals. In this role he led all commercial activities across three
"I am honored to join Indivior at such a pivotal time for the company," said Barry. "Indivior has built a strong foundation and is well-positioned to broaden its leadership position in opioid use disorder. I look forward to working with the team to grow SUBLOCADE and maximize the potential of the Indivior portfolio."
Prior to Endo, Barry spent over two decades at Sanofi with increasing levels of responsibility over a range of senior leadership positions, spanning specialty pharmaceuticals, injectables, medical aesthetics, and branded medicines, with demonstrated success in turnaround scenarios, product launches, and market development.
Barry holds an MBA from Cornell University and a bachelor's degree in public relations and marketing from McKendree University.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-patrick-barry-as-chief-commercial-officer-302465432.html
SOURCE Indivior PLC
FAQ
Who is Patrick Barry, the new CCO of Indivior (INDV)?
When will Patrick Barry start as Indivior's Chief Commercial Officer?
What will be Patrick Barry's main responsibilities at Indivior (INDV)?
What is Patrick Barry's educational background?
